Wikipedia
Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU).
Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials. Phase IIb/III dose finding and evaluation trials for fragile X-syndrome have been discontinued by the end of 2014. Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.
Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia.
In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.
Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder.
Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.